Protocol

Moxidectin in Onchocerciasis: Clinical Trial Protocols 2

Moxidectin in Onchocerciasis: Clinical Trial Protocols: MDGH-MOX-3002: Safety of a single dose of moxidectin compared with ivermectin in individuals living in onchocerciasis-endemic areas.

English version

French version

Stay up to date

Follow our work by signing up for our newsletter

Thank you for your interest in Medicines Development for Global Health.

‍Please check your email inbox and click the confirmation link to complete your subscription.

Oops! Something went wrong while submitting the form.

Navigate to

Affiliate websites

Get in touch

Medicines Development for Global Health acknowledges the sovereignty of the Peoples of the Boon Warrung/Woj Wurrung clan(s) of the Kulin nation of the land on which MDGH’s headquarters stand, and we pay our respects to their ancestors and Elders. We are here to achieve greater equity of access to good health globally, through the development of medicines for the treatment of neglected diseases, whilst respecting the right to self-determination of First Peoples everywhere.

Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523